UCLA研究人员开发了一种名为AlloESO-T的现成型T细胞疗法，由脐带血干细胞制成，能够通过两种独立识别机制靶向攻击实体肿瘤1。该疗法具备NY-ESO-1靶向受体和自然杀伤细胞受体两种肿瘤识别机制1。研究成果已发表在《Cell Reports Medicine》期刊，于2026年9月10日公开1。
在临床前研究中，单次AlloESO-T细胞给药在卵巢癌和黑色素瘤小鼠模型中实现了持久的肿瘤控制并延长了生存期1。相比之下，常规供体T细胞疗法仅产生部分肿瘤控制，且导致了移植物抗宿主病的危险并发症1。
该疗法的制造成本显著更低——从少量脐带血干细胞可在约六周内生成数万亿治疗细胞，足以供应数千剂，每剂成本仅需5000美元，远低于现有个性化T细胞疗法需要数十万美元的成本1。
这项研究目前仅在临床前实验中进行评估，尚未在人体进行临床试验，也未获得FDA批准1。
Researchers at UCLA have developed a novel off-the-shelf T cell therapy derived from cord blood stem cells called AlloESO-T, designed to target and attack solid tumors through two independent recognition systems 1. In preclinical studies using mouse models of ovarian cancer and melanoma, a single dose of the therapy achieved sustained tumor control, extended survival, and avoided dangerous side effects associated with conventional donor T cell treatments 1. The approach employs dual tumor-recognition mechanisms—a NY-ESO-1 targeted receptor and natural killer cell receptors—enabling the cells to identify cancer from multiple angles 1.
The therapeutic potential extends beyond efficacy to practical accessibility. From a small quantity of cord blood stem cells, researchers can generate trillions of treatment cells within approximately six weeks, sufficient to produce thousands of doses 1. The estimated cost per dose is approximately $5,000, substantially lower than existing personalized T cell therapies, which can cost hundreds of thousands of dollars 1. This advancement was published in Cell Reports Medicine on September 10, 2026 1.
However, the therapy remains in early development stages. The research has been evaluated only in preclinical laboratory experiments and has not yet undergone clinical trials in humans or received FDA approval 1.
评论
还没有评论，欢迎留下第一条。